Words for clinical notes
Search 5,131 terms by clinical wording, everyday description, or note example.
| Word | Plain-English search cue | Original note example | SOAP section | Writing task |
|---|---|---|---|---|
measured concentration | value obtained directly by assay | The measured concentration is recorded separately from the modeled estimate. | Objective | Drug levels - analyte, specimen and reporting |
volume of distribution | apparent volume relating amount in the body to measured concentration | The model's volume of distribution is reported with its units. | Assessment | Drug levels - exposure and pharmacokinetics |
therapeutic | within the intended treatment range or having treatment effect | The measured concentration is within the stated therapeutic range. | Assessment | Medication response and safety |
unverified administration time | time the dose was given has not been established | Unverified administration time limits how precisely the measured concentration can be timed. | Assessment | Medication response, exposure and reconciliation |
vancomycin | glycopeptide antibiotic measured for exposure monitoring in selected settings | The vancomycin report lists a measured concentration and a separate estimated AUC24. | Objective | Drug levels - named analytes and exposure reports |
yellow vision | yellow tint to vision reported by the patient | The patient reports brief yellow vision without a measured concentration yet. | Subjective | Medication history, adherence and level-related symptoms |
concentration trend reversal | serial measured levels change direction after an earlier rise or fall | Concentration trend reversal was reviewed alongside the administration timeline. | Assessment | Medication response, exposure and reconciliation |
free concentration | amount of drug measured in the unbound fraction | The phenytoin free concentration is reported separately from total drug. | Objective | Drug levels - analyte, specimen and reporting |
parathyroid hormone concentration | measured circulating hormone regulating calcium and phosphate | The parathyroid hormone concentration was assessed with concurrent calcium, phosphate and kidney function. | Objective | Glucose monitoring, endocrine testing and urine studies |
total concentration | bound and unbound drug measured together | The total concentration was measured on the same draw as free drug. | Objective | Drug levels - analyte, specimen and reporting |
corrected concentration | value adjusted mathematically using stated assumptions | The corrected concentration was calculated and is identified separately from the measured value. | Objective | Drug levels - analyte, specimen and reporting |
residual concentration | drug still measurable after a defined elapsed interval | A residual concentration was measured the day after the last recorded dose. | Objective | Drug levels - collection and dose timing |
baseline level | concentration measured before a defined change | The baseline level predates the formulation switch. | Objective | Drug levels - collection and dose timing |
lithium | mood stabilizer measured with a timed blood concentration | The lithium level is documented with the evening dose and morning draw times. | Objective | Drug levels - named analytes and exposure reports |
parent-to-metabolite ratio | parent drug concentration divided by the measured metabolite concentration | The parent-to-metabolite ratio was recorded with both analytes and collection times. | Assessment | Medication response, exposure and reconciliation |
post-hold level | drug concentration measured after therapy was held | The post-hold level was recorded with the time elapsed since the last confirmed dose. | Assessment | Medication response, exposure and reconciliation |
resumption level | concentration measured in relation to restarting an interrupted regimen | The resumption level was interpreted with the date and time therapy resumed. | Assessment | Medication response, exposure and reconciliation |
serum level | concentration measured in serum | The serum level is reported in ng/mL on the original result. | Objective | Drug levels - analyte, specimen and reporting |
whole-blood level | concentration measured in whole blood | The tacrolimus whole-blood level is listed with the assay method. | Objective | Drug levels - analyte, specimen and reporting |
acetaminophen | analgesic measured in timed exposure assessments when clinically indicated | The acetaminophen concentration is recorded alongside the reported ingestion time. | Objective | Drug levels - named analytes and exposure reports |
back-extrapolated peak | peak estimated retrospectively from a later concentration and a model | Record the back-extrapolated peak separately from the measured sample. | Plan | Drug levels - verification and documentation |
hyperosmolar state | increased concentration of dissolved particles in body fluid, interpreted with effective solutes specified | Hyperosmolar state was characterized with glucose, sodium and measured osmolality. | Assessment | Acid-base and electrolyte interpretation |
model fit | agreement between a model and measured observations | Review the model fit against the timed concentrations. | Plan | Drug levels - verification and documentation |
observed-to-predicted ratio | measured value divided by the model prediction at that time | The observed-to-predicted ratio was recalculated after the collection time was corrected. | Assessment | Drug concentrations, exposure and assay interpretation |
procainamide | antiarrhythmic whose active metabolite may also be measured | The procainamide and metabolite concentrations are shown separately. | Objective | Drug levels - named analytes and exposure reports |